SCHEMBL5356355

SCHEMBL5356355

CN(C)c1ccc(CNC(=O)[C@](N)(CSCC2CCCCC2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC3 O15379 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 3/20 0.35
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.34
CA2 P00918 1/20 0.34
EPHX2 P34913 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755414 0.88 ALDH1A1 (0.47) LMNAMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL5757246 0.88 ALDH1A1 (0.47) LMNAMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL5752916 0.85 EPHX1 (0.45) MAPTALDH1A1POLBSMN1; SMN2CA2
SCHEMBL5343462 0.84 CACNA1B (0.40) GAALMNAMAPTHDAC1HDAC2
SCHEMBL5356343 0.77 CTSD (0.37) GAALMNAMAPTHDAC1HDAC2
SCHEMBL5349622 0.76 HDAC1 (0.36) GAALMNAMAPTHDAC1HDAC2
SCHEMBL5356337 0.75 CACNA1B (0.46) CYP3A4POLB
SCHEMBL5349008 0.74 ALDH1A1 (0.48) ALDH1A1RAB9ASMN1; SMN2NPC1EPHX2
SCHEMBL5356190 0.74 ALDH1A1 (0.48) ALDH1A1RAB9ASMN1; SMN2NPC1EPHX2
SCHEMBL5352506 0.74 ALDH1A1 (0.48) ALDH1A1RAB9ASMN1; SMN2NPC1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166590-B2 Amino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-23 US disclosed
US-20030013725-A1 Amino acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013725-A1 Amino acid derivatives CACNA1B, SCN1A, SCN2A GAA 3754/4885LMNA 2257/4885MAPT 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.